Astellas Pharma Inc. (ALPMY) Stock

About Astellas Pharma Inc.

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. The company's diverse pipeline and marketed portfolio address critical unmet medical needs across various therapeutic areas. In oncology, Astellas offers XTANDI, an androgen receptor signaling inhibitor used in prostate cancer; XOSPATA, a FLT3 inhibitor designed for adults with relapsed or refractory acute myeloid leukemia characterized by a FLT3 mutation; and PADCEV, a treatment option for patients with locally advanced or metastatic urothelial cancer. For urological conditions, key offerings include Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist managing urgency, urinary frequency, and urge urinary incontinence, alongside Vesicare for overactive bladder and mirabegron specifically for pediatric neurogenic detrusor overactivity. Other urology-related products include Eligard for prostate cancer and Harnal/Omnic for benign prostatic hyperplasia. Beyond oncology and urology, the company provides Evrenzo, an oral medication for anemia linked to chronic kidney disease, and the immunosuppressant family Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ rejection in transplant recipients. Funguard/MYCAMINE serves as an antifungal agent. Astellas actively engages in numerous strategic collaborations to expand its innovation pipeline. These include clinical trial partnerships with Merck & Co., Inc. and CytomX Therapeutics, Inc., as well as an innovative agreement with BANDAI NAMCO Entertainment Inc. to develop a smartphone-based exercise support application. Further alliances encompass a strategic research partnership with Harvard University focused on therapeutics and technologies, a research collaboration with Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies using its Antibody Warhead Enabling platform, and an agreement with Zenith Epigenetics Ltd. for the evaluation of ZEN-3694. The company also maintains a collaboration with Cytokinetics, Incorporated, and has forged a strategic partnership and license agreement with Minovia Therapeutics Ltd. to develop cell therapy programs addressing diseases stemming from mitochondrial dysfunction. Founded in 1923, Astellas Pharma Inc. maintains its corporate headquarters in Tokyo, Japan.

Astellas Pharma Inc. is headquartered in JP.

Astellas Pharma Inc. (ALPMY) stock trades at $13.13 with a market capitalization of $23.52B. The stock is valued at a price-to-earnings (P/E) ratio of 13.19, price-to-book of 2.11, price-to-sales of 1.80. Over the past 52 weeks the stock has ranged between $9.46 and $17.35, and currently trades 24.3% below its 52-week high. It pays a dividend yielding 3.12%.

On profitability, Astellas Pharma Inc. generates a return on equity (ROE) of 17.44%, above the typical market average, return on capital employed of 17.24%, an operating margin of 18.92%, a net profit margin of 13.63%.

In its most recent fiscal year, Astellas Pharma Inc. reported annual revenue of $2.27T, net profit of $309.1B, revenue has compounded at 12.7% a year over the last five years, profit at 20.7% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.31 — a conservative balance sheet with little leverage risk, a current ratio of 1.17, total assets of $3.58T, $282.8B in cash and equivalents.

ALPMY has an average daily trading volume of 190,765 shares, a beta of 0.08 (less volatile than the overall market).

Official website: www.astellas.com